Evopoint Biosciences Inc.

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Claudin 18.2 (CLDN18.2)Antibody–drug conjugate
Non-Small Cell Lung CancerGastric Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ASP546CPhase 1/2Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract Cancer …
Est. primary completion 2026-12-30 · NCT06792435 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
ASP546CPhase 1/2Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Est. primary completion 2029-07-31 · NCT07488676 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.